Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Canagliflozin (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms COMETA
- Sponsors Janssen Research & Development
- 07 Sep 2017 Planned End Date changed from 30 Apr 2018 to 29 Jun 2018.
- 07 Sep 2017 Planned initiation date changed from 29 Aug 2017 to 9 Oct 2017.
- 01 Sep 2017 New trial record